Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Table 4 Correlation between the changes of LDL-C subspecies, HDL-C subspecies and the changes of lipid parameters

	ΔHDL-C (mg/dL)		ΔHDL2-C (mg/dL)		ΔHDL3-C (mg/dL)		ΔHDL-C (mg/dL)		ΔHDL2-C (mg/dL)		ΔHDL3-C (mg/dL)
	r	p	r	p	r	p	r	p	r	p	r	p
ΔTG (mg/dL)	−0.156	0.341	−0.125	0.446	−0.069	0.674	−0.176	0.277	−0.074	0.646	−0.228	0.155
ΔLDL-C (mg/dL)	0.295	0.067	0.167	0.306	0.239	0.142	0.555	<0.001*	0.254	0.113	0.307	0.053
Δsd LDL-C (mg/dL)	0.183	0.262	−0.066	0.688	0.411	0.009*	0.192	0.240	−0.036	0.825	0.392	0.013*
Δlb LDL-C (mg/dL)	0.760	0.641	0.171	0.297	−0.134	0.413	0.288	0.071	0.561	<0.001*	0.307	0.053
Δapo AI (mg/dL)	0.890	<0.001*	0.697	<0.001*	0.450	0.004*	0.808	<0.001*	0.516	0.002*	0.489	0.003*
Δapo AII (mg/dL)	0.647	<0.001*	0.394	0.012*	0.500	0.001*	0.633	<0.001*	0.354	0.034*	0.446	0.007*
ΔapoB (mg/dL)	0.283	0.080	0.240	0.141	0.105	0.522	0.368	0.019*	0.135	0.406	0.230	0.153
ΔapoCIII (mg/dL)	0.309	0.055	0.234	0.149	0.156	0.340	0.132	0.415	0.026	0.871	0.100	0.538

r coefficient of correlation, TG triglycerides, LDL-C low-density lipoprotein-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, Apo apolipoprotein, HDL-C high-density lipoprotein-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
* p < 0.05

ISSN: 1475-2840